- A recent study published in JAMA Network Open suggests that GLP-1 medications like Ozempic and Wegovy may reduce the risk of several obesity-associated cancers in individuals with type 2 diabetes. Overweight and obese individuals face heightened risks for 13 types of cancer, and excess weight contributes significantly to new cancer diagnoses. The study, analyzing data from nearly 1.7 million people with type 2 diabetes, found that those treated with GLP-1 drugs had significantly lower risks for 10 of these cancers compared to those treated with insulin. Reductions in risk were particularly notable for gallbladder, pancreatic, and liver cancers, among others. While GLP-1 treatment did not mitigate the risk of postmenopausal breast cancer, stomach cancer, or thyroid cancer, the study underscores the potential of GLP-1 medications in cancer prevention, alongside lifestyle changes and bariatric surgery, warranting further investigation into their broader implications for cancer risk management in high-risk populations. (Article here)
July 17, 2024
Life Sciences | Tea Leaves